There is extensive evidence from the molecular and genomic analysis of human cancers that the PI 3-kinase (phosphoinositide 3-kinase)–Akt/PKB (protein kinase B) pathway is deregulated in malignant progression. Furthermore, the causal involvement of PI 3-kinase is supported by gene-knockout mouse models. Prototype inhibitors show evidence of anticancer activity in vitro and in vivo animal models. The recent development of isoform-selective inhibitors shows considerable promise for cancer treatment.
Conference Article| April 01 2004
Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment
Biochem Soc Trans (2004) 32 (2): 393-396.
- Views Icon Views
- Share Icon Share
- Cite Icon Cite
P. Workman; Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Trans 1 April 2004; 32 (2): 393–396. doi: https://doi.org/10.1042/bst0320393
Download citation file: